Corporate Investor

Updated:

Jeekai & Partners

Jeekai & Partners was established in Beijing in 1998 by Robin R. Zhao, who continues to lead the firm as Senior Partner. The founding predates most structured...

Jeekai & Partners logo

Jeekai & Partners

Jeekai & Partners was established in Beijing in 1998 by Robin R. Zhao, who continues to lead the firm as Senior Partner. The founding predates most structured IP investment vehicles in China, positioning the firm as an early mover in the specialized intersection of intellectual property law and principal investment. Zhao's team includes patent administration head Mo Guo and a network of professionals affiliated with major industry bodies, reflecting a model built on legal-operational capability rather than traditional fund management. The firm concentrates exclusively on intellectual property markets, a narrow mandate that spans patent origination, acquisition, and monetization within China. The firm also maintains a philanthropic vehicle, the Beijing Jiekai Cardiovascular Health Foundation, which operates as a separate entity under the family's broader interests. What distinguishes Jeekai structurally is its dual identity as both IP law firm and principal investor — a hybrid rare outside specialized litigation-finance circles in the West.

Website
jeekai.com

General information

Firm type

Corporate Investor

Year founded

1998

Location

Region

Asia

Country

China

City

Beijing

Corporate office

Beijing, China

Principals

Robin R. Zhao

Senior Partner & Founder

Mo Guo

Manager, Patent Administration Department

Xiaoman Gu

Former Partner

Sector focus

Intellectual Property

Frequently asked questions

What does Jeekai & Partners actually invest in?

Jeekai concentrates on intellectual property assets — primarily patents and trademarks within China. The firm originates, acquires, and manages IP portfolios as a corporate investor, meaning it directly owns the assets rather than operating a third-party fund. This investment focus covers the full lifecycle of IP, from prosecution to monetization.

How does Jeekai source intellectual property deals?

The firm is deeply embedded in China's IP professional ecosystem. It holds memberships in the International Trademark Association (INTA), AIPPI, and the All-China Patent Agents Association (ACPAA), which provide structural access to patent applicants, trademark filers, and enforcement actions. This network-based sourcing model is paired with in-house patent prosecution capabilities that can surface investment opportunities during the application process.

What is the Beijing Jiekai Cardiovascular Health Foundation?

The Beijing Jiekai Cardiovascular Health Foundation is a philanthropic entity maintained separately from Jeekai & Partners' investment activities. It reflects the firm's or founder's broader interests in healthcare philanthropy within China. There is no public indication of commingling between the foundation's assets and Jeekai's IP investment operations.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Beijing Corporate Investor profiles